Immune-Onc further strengthens IP coffers through Univ. of Texas in-licensing
Executive Summary
Immune-Onc Therapeutics Inc. (therapeutic antibodies for cancer) continues to build up its intellectual property portfolio, this time through a licensing agreement with the University of Texas Health Science Center at Houston and the University of Texas Southwestern Medical Center, both part of the University of Texas system.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice